Raloxifene in Reducing the Risk of Postmenopausal Fracture amongst Osteoporotic Subjects

ABSTRACT

Background: Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent decrease in bone mineral density (BMD) and increase in bone fragility and susceptibility to fracture. Hence; we planned the present study to assess the effect of raloxifene in reducing the risk of postmenopausal fracture amongst osteoporotic subjects. Methods: The present study included assessment of effect of raloxifene in reducing the risk of postmenopausal fracture amongst osteoporotic subjects. A total of 120 postmenopausal women were included in the present study. All the subjects were broadly divided into two broad groups with 60 subjects in each group; Group A Subjects who were given placebo for two years Group B Subjects who were given raloxifene 60 mg/d for 2 years. Assessment of Risk of Postmenopausal Fracture in all the subjects was done by evaluating the bone mineral density (BMD) at two years follow-up time. All the results were compiled and assessed by SPSS software. Results: Non- significant results were obtained while comparing the adverse effects among subjects of both the study groups. Overall incidence of new vertebral fractures among subjects of group A and group B included 6 and 4 percent respectively. Significant results were obtained while comparing the incidence of new vertebral fractures among subjects of group A and group B respectively. Conclusion: Significant reduction in the risk of fractures occur under the influence of raloxifene in postmenopausal women with osteoporosis.